Petra Kolenc (Petra Kolenc Peitl)

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 4

Top Topics

Induced Pluripotent Stem Cells

Top Venues

Pharmaceuticals (Basel, Switzerland)

This page only lists publications with an associated author ORCID identifier.

Publications

Doroteja Novak, Barbara Janota, Anton Amadeus Hörmann, Agnieszka Sawicka, Marko Kroselj, Alicja Hubalewska-Dydejczyk, Melpomeni Fani, Renata Mikolajczak, Petra Kolenc, Clemens Decristoforo, Piotr Garnuszek
Development of the 99m Tc-Labelled SST 2 Antagonist TECANT-1 for a First-in-Man Multicentre Clinical Study. Pharmaceutics 15 (3) (2023)
Doroteja Novak, Barbara Janota, Anton Amadeus Hörmann, Agnieszka Sawicka, Marko Kroselj, Alicja Hubalewska-Dydejczyk, Melpomeni Fani, Renata Mikolajczak, Petra Kolenc, Clemens Decristoforo, Piotr Garnuszek
Development of the 99m Tc-Labelled SST 2 Antagonist TECANT-1 for a First-in-Man Multicentre Clinical Study. Pharmaceutics 15 (3) (2023)
Doroteja Novak, Barbara Janota, Anton Amadeus Hörmann, Agnieszka Sawicka, Marko Kroselj, Alicja Hubalewska-Dydejczyk, Melpomeni Fani, Renata Mikolajczak, Petra Kolenc, Clemens Decristoforo, Piotr Garnuszek
Development of the 99m Tc-Labelled SST 2 Antagonist TECANT-1 for a First-in-Man Multicentre Clinical Study. Pharmaceutics 15 (3) (2023)
Melpomeni Fani, Viktoria Weingaertner, Petra Kolenc, Rosalba Mansi, Raghuvir H Gaonkar, Piotr Garnuszek, Renata Mikolajczak, Doroteja Novak, Urban Simoncic, Alicja Hubalewska-Dydejczyk, Christine Rangger, Piriya Kaeopookum, Clemens Decristoforo
Selection of the First 99mTc-Labelled Somatostatin Receptor Subtype 2 Antagonist for Clinical Translation-Preclinical Assessment of Two Optimized Candidates. Pharmaceuticals (Basel, Switzerland) 14 (1) (2020)